熱門資訊> 正文
Protalix BioTherapeutics任命Gilad Mamlok为首席财务官
2025-07-21 19:00
- Protalix Biotherapeutics, Inc.(PLX) 0
- VictoryShares US 500 Enhanced Volatility Wtd ETF(CFO) 0
- Informatica Inc.(NYSE) 0
- Protalix BioTherapeutics (NYSE:PLX) Monday announced the appointment of Gilad Mamlok to serve as the company's new Senior Vice President and Chief Financial Officer, effective August 24, succeeding Eyal Rubin.
- To ensure a seamless transition, Mamlok has joined the company and is working alongside Rubin.
- After his tenure as Chief Financial Officer ends, Rubin will continue to be available to the Company as necessary until October 2025.
- Most recently, he served as the CFO of TytoCare, a privately held company in the remote healthcare space.
More on Protalix BioTherapeutics
- Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript
- Protalix BioTherapeutics targets phase 2 launch for PRX-115 in H2 2025
- Protalix BioTherapeutics Q1 Earnings Preview
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
- Historical earnings data for Protalix BioTherapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
